BELS Advisory Council

Members of the BELS Advisory Council provide advice and recommendations to the BELS management team on building the organisation and connections to benefit the BELS community and UK plc. Members represent varied interests across the global health and  life sciences. They coalesce around the shared goal of improving healthcare and advancing medical innovation to benefit patients and UK plc, as well as helping the organisations at which they work and hold advisory roles.

The nature of service on the BELS Advisory Council is advisory, voluntary and participatory. Members are selected for their expertise; participants receive no compensation. There is an expectation for active involvement and mutual benefit from service.

BELS Advisory Council Members

Mark Bamforth – President & CEO – Arranta Bio, Cambridge MA, USA
Mark is leading Arranta Bio, a new CDMO he established in 2019 to serve companies targeting the human microbiome.  Previously, he founded and ran Brammer Bio, a premier contract manufacturer which was acquired by Thermo Fisher and Gallus BioPharmaceuticals which he merged with Laureate Pharma in 2013 and sold to DPx Holdings in 2014, supporting the integration into DPx’s Patheon Biologics business.  He has 26 years of previous experience in the UK and USA running global operations and a pharmaceutical CMO business for Genzyme and began his career as a chemical engineer in the whisky industry and as a petroleum engineer exploring for North Sea oil.  Mark is on the board of Avid Bioservices, serves on the MassBio Board and is a Trustee of Wentworth Institute of Technology in Boston and Entrepreneurial Scotland, enabling young Scottish entrepreneurs to expand their business knowledge through education and internships with high growth US companies.  He is an Operating Partner of Ampersand Ventures and has a BSc in Chemical Engineering from the University of Strathclyde and an MBA from Henley Management College.

Dominic Behan 1 Dr Dominic P Behan, Chief Executive Officer – Sentia Medical Sciences, San Diego CA, USA
Dominic has 27 years of experience in the pharmaceutical industry. His industrial career began at Neurocrine Biosciences and in 1997 he co-founded Arena Pharmaceuticals and was elected to the Board of Directors in 2000, latterly serving as Executive Vice President and Chief Scientific Officer.  He continues to serve as a consultant and chairs the Scientific Advisory Board. In 2016, Dominic co-founded Beacon Discovery, a privately held drug discovery incubator, before founding Sentia Medical Sciences in 2017 which is developing novel peptide therapeutics to cure stress related disorders.  He also serves on the Scientific Advisory Board of Keystone, a world renowned organization responsible for establishing and arranging meetings of scientific excellence. Dominic obtained a BSc in Biochemistry from the University of Leeds and a PhD in Biochemistry from the University of Reading, investigating the biology of stress. He then spent three years as a Post-Doctoral Research Fellow at the Salk Institute in San Diego. He also received a higher doctorate (DSc) degree from the University of Reading where he was appointed Visiting Professor.

Dr Timothy P Clackson, PhD – President & EVP of R&D – Xilio Therapeutics, Cambridge MA, USA
Before joining Xilio (previously Akrevia Therapeutics),  a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, Tim was President of R&D and Chief Scientific Officer at ARIAD Pharmaceuticals, an integrated oncology company headquartered in Cambridge MA and Lausanne, Switzerland.  During his 19 year career at ARIAD, Tim held a series of increasingly senior positions, including CSO from 2003 and President of R&D from 2010. He had overall operational and strategic responsibility for R&D at ARIAD, including drug discovery, preclinical and translational research, clinical development, and technical operations before the company was sold to Takeda in February 2017.   Prior to ARIAD, he was a postdoctoral fellow at Genentech.   His graduate research, conducted with Dr. Greg Winter, the winner of the 2018 Nobel Chemistry prize at the MRC Laboratory of Molecular Biology in Cambridge (UK), included the development of antibody phage display library technology and led to the founding of Cambridge Antibody Technology (CAT) and the subsequent development of multiple approved antibody products.  He received his PhD in Biology from Cambridge University and his BA degree in Biochemistry from Oxford University.

GaryClements

Dr Gary J Clements – VP Business Development – Kymab Ltd, Cambridge UK
Gary is a transaction-orientated business development professional with experience in pharma and smaller biotech businesses.  His current role is VP of Business Development at Kymab Limited (Cambridge UK), a biotech focused on antibody-based therapeutics applied to immunotherapy and anti-infective drug candidates.  Prior to this he was Head of Research Collaborations and Divestments within the Business Development leadership team at Shire Pharmaceuticals where he spent 13 years including a two-year secondment to their Massachusetts offices.  Gary entered the biotech industry when he joined Celltech in 1986 upon completing his a PhD research at Warwick University.

Dr Ronald Farquhar – Biotech Investor – Morningside, Newton MA, USA
Ronald (Ronnie) Farquhar studied microbiology both as an undergraduate (BSc Edinburgh) and as a postgraduate (PhD Oxford).  Over the next 5 years Ronnie worked at Shell Research (microbial production of biofuels) and as a Merck-sponsored postdoctoral fellow at the University of Kent.  Ronnie joined Pfizer Research in Sandwich, Kent in 1988 and over the following 10 years worked within infection discovery, focused on antifungals and antivirals.  In 1998 Ronnie joined Millennium Pharmaceuticals where he ran the company’s major alliances with Pfizer and Wyeth (in infection) and with Bayer (in early discovery).  Following this, Ronnie served as head of preclinical and discovery biology at ActivBiotics (antibacterial drug discovery) and subsequently as head of Charles River Labs’ Preclinical Services.  From 2009-2015, Ronnie led discovery and pharmaceutical research at Cubist Pharmaceuticals until its acquisition by Merck at the end of 2014. Ronnie joined Morningside Ventures in 2015 as an entrepreneur-in-residence, charged with creation of new infectious disease- and microbiome-related opportunities.  In February 2016 Ronnie founded Artugen Therapeutics to exploit recent advances in microbiome science, in May of 2016 he founded Bacainn Biotherapeutics, focused on exploiting a novel pathway responsible for chronic inflammation, and in 2017 he founded ClearB Therapeutics to develop therapeutic vaccines to redirect patients’ immune systems toward functional cure of hepatitis B.  He is CEO and board member of all three companies.

Dr Will Harvey – Professor of Management, Associate Dean (Research & Impact) – University of Exeter Business School – Exeter UK
Will Harvey is an Associate Dean and Professor at the University of Exeter Business School, an Associate Fellow in the Centre for Corporate Reputation at the University of Oxford and an Honorary Senior Lecturer at the University of Sydney. Will’s research focuses on reputation, leadership, expatriates, migration and talent management. He received his BA from Durham University and an MPhil and PhD from the University of Cambridge and has published in a range of journals on subjects such as business and management, sociology, geography and industrial relations.  Over the past five years, Will has taught undergraduate, postgraduate, MBA and EMBA students at the University of Cambridge, the University of Oxford, the University of British Columbia, the University of Sydney and the University of Exeter.

Dr Stephen Hill – CEO – Faraday Pharmaceuticals, Seattle WA, USA
Steve was appointed as CEO of Faraday Pharmaceuticals in September 2015, a role to which he brought over 20 years of previous industry experience.  Faraday is pursuing the development of elemental reducing agents based on the pioneering work of Mark Roth from his lab at the Fred Hutchinson Cancer Research Center in Seattle.  Previously, he held the position of President, Chief Executive Officer and member of the Board of Directors at Targacept and prior to that served as President and Chief Executive Officer of Solvay Pharmaceuticals, where he led an organisation of over 1,200 employees until its acquisition by Abbott Laboratories in 2010, and of ArQule, where he led a successful transition from a fee-for-service discovery chemistry model to an enterprise with a proprietary clinical-stage pipeline.  Prior to ArQule, Stephen held several leadership positions with F. Hoffmann-La Roche Ltd., including Global Head of Clinical Development.  He is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.  In addition to Faraday, Stephen sits on the boards of Catalyst Bioscience, Cellectar Biosciences and Lipocine.

Dr Joanna Horobin, MB, ChB, MRCGP –Independent Director, Boston MA, USA
Joanna has over 30 years of successful pharmaceutical development and leadership.  Joanna is on the boards of Kymera Therapeutics (Cambridge MA), Liquidia Technologies (Morrisville, NC) and Nordic Nanovector (Norway).  She is the former Senior Vice President and Chief Medical Officer at Idera Pharmaceuticals, a company developing oligonucleotides for rare diseases, including rare cancers.  Prior to joining Idera, she was the CMO of Verastem and previously served as CEO of Syndax Pharmaceuticals.  Earlier, she held several roles of increasing responsibility at global pharmaceutical corporations such as CombinatoRx and Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the global oncology business unit’s launch which included the launches of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer.  She also led a successful joint venture with Chugai to launch Granocyte® (lenograstim).  Prior to this, Joanna played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® and Relafen®/ Reliflex®.  Before joining the industry Joanna was a GP in West London. She received her medical degree from the University of Manchester and gained membership of the Royal College of General Practitioners and the Faculty of Pharmaceutical Medicine.

John Houghton – Global Medicine Leader – AstraZeneca, Gaithersburg MD, USA
John has extensive US and International experience in the pharma, biotech and medical device industries.  He has direct experience in building out global commercial organisations including marketing, sales and new product development.  He has also been directly responsible for successfully licensing products and leading joint ventures and partnerships.  John is currently Global Medicines Leader at AstraZeneca in the US, having previously been President and CEO of Nephros, a publicly traded medical device company focused on ultrafiltration of liquids particularly for use in dialysis.  Prior to Nephros he served as President and CEO of CorMedix, a pharmaceutical company he helped found and was responsible for taking through an IPO.  Before joining CorMedix, John established the global sales and marketing infrastructure for the Biotech division of Stryker.  Prior to Stryker, he worked for Aventis and predecessor companies.  During his time at Aventis he led the global marketing of Nasacort, served as commercial lead on the Aventis-Millennium inflammation collaboration, and functioned as the global new products commercialisation head for respiratory, inflammation, cardiovascular, and metabolism products.  John received his BSc from Liverpool John Moores University.

Dr Annalisa Jenkins, MBBS, MRCP – Chair of Board of Directors– Cell Medica, London
A biopharma thought leader with nearly 20 years of industry experience, Annalisa has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Currently she chairs or serves on the boards of a number of private and public life science organisations in the US and UK, including Chair of the board of Cell Medica, Chairman of the Court of the London School of Hygiene and Tropical Medicine, a board member of Faster Cures, and member of the Science Advisory Board of the FDA, which advises FDA leadership on complex scientific and technical issues. She was the President and CEO of Dimension Therapeutics, and earlier served as executive vice president, head of Global Research and Development for Merck Serono. She also led Global Medical Affairs and Quality and was a member of Merck Serono’s Pharmaceutical Executive Committee. Previously, she pursued a nearly 15-year career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs. Annalisa began her career as a medical officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. She graduated in medicine from St. Bartholomew’s Hospital London and trained in cardiovascular medicine in the UK National Health Service. Annalisa is a member of the Board of Directors of Ardelyx, Biothera, MedCity, and Viventia Bio, Inc. She also is a member of the European Commission’s Scientific Panel for Health, a science-led expert group tasked with helping to achieve better health and wellbeing for all.

Dr Jeremy Levin – Chairman & CEO – Ovid Therapeutics, Lewes DE, USA
Jeremy is the Chairman and CEO of Ovid Therapeutics, a private company developing novel medicines for orphan diseases of the brain.  In 2012, FierceBiotech voted him as one of the 25 most influential people in the biopharmaceutical industry.  He also currently chairs the Board of Directors of the Biotechnology Innovation Organization (BIO) and sits on the board of Lundbeck.  Previously he served as President and CEO of Teva Pharmaceutical Industries Ltd. where he was responsible for overseeing all aspects of one of the world’s largest pharmaceutical companies.  Prior to this he was a member of the executive committee of Bristol-Myers Squibb where he had global responsibilities for strategy, alliances and all transactions: operations representing nearly 50% of the revenue of BMS.  In this role Jeremy devised and led the BMS String of Pearls Strategy which resulted in the transformation of the company pipeline.  Prior to BMS, he held the position of Global Head of Strategic Alliances at Novartis.  In this role, he established and managed strategic collaborations with multiple companies around the world.  Prior to Novartis, Jeremy was a director and officer of several public and private biotechnology organisations including Cadus Pharmaceuticals which he took public as CEO.  Jeremy is the recipient of a number of awards including the Kermode Prize for work on novel hypertension drugs, the Albert Einstein Award for Leadership in Life Sciences awarded by Shimon Peres, the B’nai B’rith Award for Distinguished Achievement for commitment to improving global health care, to philanthropy, community service and industry leadership and the Officer’s Cross of the Order of Merit of the Republic of Hungary.  Having grown up in South Africa, Jeremy holds a BA in Zoology and was awarded a MA and a PhD in the structure of Chromatin from the University of Oxford in 1978.  He also received degrees of Bachelor of Medicine, Bachelor of Surgery from the University of Cambridge in 1981 and has practiced internal medicine at University Hospitals in England, Switzerland and South Africa.

Dr Alan Lewis – Serial board member, San Diego CA, USA
Alan is an industry veteran with nigh on 40 years of experience as an executive in the life science industry.  He is the founder and chairman at Batu Biologics (La Jolla CA). He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was latterly Vice President of Research, leading translational research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases.  He later became the CEO of Signal Pharmaceuticals, a San Diego company focusing on small-molecule drug discovery and development, which was eventually acquired by Celgene in 2010.  Subsequent to his employment as President of Celgene, Dr. Lewis had several successful business ventures, including raising $27 million as CEO of Novocell, becoming the CEO of the Juvenile Diabetes Research Foundation, and raising over $45 million as CEO of Ambit Biosciences.  He currently also chairs Cellastra (San Francisco) and is on the boards of Assembly Biosciences (South San Francisco CA), BioMarin (San Raphael CA), Capella Therapeutics (La Jolla CA), and ScanCell Holdings (Oxford UK).  Alan received a BSc in Physiology and Biochemistry from the University of Southampton and a PhD in pharmacology from the University of Wales in Cardiff, after which he completed  completed a postdoctoral fellowships at the University of Guelph and at  at Yale.  He was awarded an Honorary Fellowship from the University of Wales in Swansea.

Dr Daniel Mahony – Co-head Healthcare – Polar Capital,   London UK
Dan joined Polar Capital to set up the healthcare team in 2007 with his colleague Gareth Powell and the team now has approximately $2.5 billion in assets under management. He has 25 years of experience in healthcare, including more than 18 years in the investment arena as a portfolio manager and sell-side analyst. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotech sector. Before working in the investment field, Daniel worked as a research scientist for seven years mainly at Schering Plough/DNAX Research Institute in California.  He received his PhD from Cambridge University and a first class honours degree in biochemistry from Oxford University.  Dan is a board member of Celmatic (New York), Keepabl (London), and the UK BioIndustry Association.

Dr Allan Marchington – Managing Partner – Bridge Valley Ventures,  Cambridge UK
Allan is a Managing Partner at Bridge Valley Ventures, a life sciences venture capital fund based in the UK and investing on a global basis in Europe and North America.  Before founding Bridge Valley Ventures in 2018, Allan spent 13 years in the healthcare venture capital industry at Apposite Capital and Abingworth.  He was a Founding Partner at Apposite Capital, a healthcare focused venture firm with over $200m under management.  Prior to moving into the venture industry, he was CEO of Cambridge Discovery Chemistry, a company which he founded and successfully sold to Millennium Pharmaceuticals.  Following the acquisition Allan moved to the US to take up the role of Senior Vice President of Technology at Millennium.  Allan started his career working for 7 years as a medicinal chemist at Pfizer.  He is currently an active Board member of Bird Rock Bio Inc. (San Diego, CA) and Calchan Ltd (London UK).  He is also a member of the Royal Society of Chemistry’s Investment Committee.  Allan formerly served on the boards of Ambit Biosciences Inc, Ambrx Inc., the BioIndustry Association, Convergence Pharmaceuticals Ltd,  Pharmakodex Ltd,  and Sotera Wireless Inc.  He earned a PhD in Chemistry from the University of Liverpool.

Dr Sean McCarthy – CEO – CytomX Therapeutics, South San Francisco CA, USA
Sean has more than 20 years of experience in the biotechnology industry, including business development, venture capital, program management and research management.  Prior to joining CytomX in January 2011, he was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies and new company formation.  Prior to Pappas, Sean was the vice president of business development at SGX Pharmaceuticals where he spearheaded a wide range of strategic partnerships with major pharmaceutical companies, including a $515 million oncology alliance with Novartis, and led a strategic re-orientation that resulted in the successful initial public offering of the company in 2006.  Prior to SGX, he was associate director of program management at Millennium Pharmaceuticals, where he managed therapeutic protein programs and a research team that invented novel genomic techniques for the identification of novel biologics.  He received his BSc in biochemistry and pharmacology at King’s College, University of London, his MBA from the Rady School of Management at UC San Diego and a PhD in cancer biology from St. John’s College, University of Oxford.

Dr Vincent Miles – Partner – Abingworth Management, Waltham MA, USA
Vin has more than 40 years of management experience in the biotechnology industry.  Before joining the venture capital firm of Abingworth, he was Senior Vice President Business Development of the Abingworth portfolio company Alnylam Pharmaceuticals.  Previously, Vincent was at Millennium Pharmaceuticals, where he held VP positions in business development, strategic planning and corporate communications.  Formerly he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia, having begun his career at Amersham International in R&D.  Vincent is on the boards of Chiasma and Hydra Biosciences.  He has a BSc in biochemistry and a PhD in molecular biology from University College London and is based in Abingworth’s Boston office.

Dr Stephen Naylor – Founder, Chairman and CEO – ReNeuroGen LLC, Milwaukee, WI, USA
Steve leads ReNeuroGen, a company focused on adjuvant therapies for stroke, multiple sclerosis, traumatic brain injury, and chronic traumatic encephalopathy. He has over 30 years of experience in the Health and Life Sciences in both the academic and private sectors. He is also Founder, and former Chairman and COO of Intrinsic Metabolic Biopharma (Phoenix, AZ), a therapeutic drug development effort in hypertriglyceridemia, and a Board Adviser to CureHunter (Portland, OR) which is focused on Drug Repurposing. He is also the Founder, Chairman and CEO of MaiHealth (Indianapolis, IN) a molecular bioprofile diagnostics company in the health and wellness sector. He was also former Founder, Chairman and CEO of Predictive Physiology and Medicine (2005-2010), one of the world’s first personalized medicine companies offering a series of information content tools to consumers.  He has published ~300 scientific articles, filed over 20 patents and helped raise in excess of $100 million in federal grants and equity investments for the companies he has been associated with over the past decade.  Stephen has degrees from the University of East Anglia (BSc-1st Class Honors-Chemistry), University of Southampton (MSc-Oceanography), University of California (MS-Chemical Sciences) and University of Cambridge (PhD-Analytical Biochemistry /Chemistry) and was also was a Postdoctoral Fellow at MIT.  Over the years he has worked at the MRC (UK), Mayo Clinic (US) and the world’s first systems biology company Beyond Genomics, as well as helped found numerous small start-up entities, all in the US.

.

Dr David Paterson – Sr Leadership Team for Research, Translation & Commercialisation – Colorado State University
Before joining the Colorado State senior leadership team, David held a number of business and corporate development responsibilities, including leadership positions in both Dublin and Amsterdam for Impax Laboratories. Previously he has served as Vice President of Alliance Management and VP of Business Development at Impax Labs in California. Prior to Impax, David was Senior Director of Business Development at Sepracor (now Sunovion Pharmaceuticals) where his primary responsibilities included CNS and drug discovery in-licensing.  Prior to Sepracor, David was the Director for US Academic Liaison in the Worldwide Business Development Group at GlaxoSmithKline.  Before joining GSK he was a VP of Business Development at SkyePharma and helped establish a business development presence for SkyePharma in the US.  Prior to that he was Director of Technology Transfer at the Penn State University School of Medicine in Hershey, Pennsylvania .  His experience covers the business development function in both branded and generic pharmaceuticals, identifying and sourcing strategic business opportunities, mergers, acquisitions, alliances and/or joint ventures. David earned his BSc in Botany from the University of Glasgow and received his PhD (Plant Biology) from the University of Illinois at Urbana-Champaign.

Dr Avi Spier, Executive Director, Head of Search & Evaluation/Region UK—Novartis Institute for Biomedical Research, Boston MA, USA
Avi has over 15 years of experience at Novartis, having joined the Genomics Institute of the Novartis Research Foundation as its Head of Business Development in 2004. In 2012, Avi moved into Novartis BD&L where he is now directs activities for a range of therapeutic areas and disciplines, and with a particular focus on the UK. Having trained as a postdoc at The Scripps Research Institute in California, in 2001, Avi co-founded La Jolla based Allon Therapeutics where he led the peptide therapeutic neurodegenerative disease focused company as its President and CEO through two financing rounds and up to its entry onto the Toronto Stock Exchange. He was educated in Biological Sciences at Oxford University and received his PhD in molecular neuroscience from Cambridge University at the MRC-Laboratory of Molecular Biology. Avi has a keen desire to see the sector move from strength to strength in the UK.  His background, in both a start-up biotech organisation and in BD&L for a large company enables him to understand the wide spectrum of needs from both ends of the sector as well as bringing insights and connections from across the Atlantic. At his core, Avi sees himself as an innovator with a passion for seeking ways to improve how efficiently great research can robustly find its way through our complex industry and reach patients and communities who are in need. Avi joined the board of the UK BioIndustry Association in January 2020.

Dr David U’Prichard – CSO of BioMotiv – Cleveland OH, USA
David’s near 40-year professional career spans academic research, senior R&D leadership at two global pharmaceutical companies, biotech company leadership, venture capital, and extensive experience on the boards of public and private US, UK, European and Indian companies.  For some 10 years, David was a Venture Partner at Red Abbey Venture Partners, Apax Partners and Care Capital.  From 1999 to 2003, he was CEO of 3-Dimensional Pharmaceuticals, which he took public in 2000 and sold to Johnson & Johnson.  From 1997 to 1999, he served as Chairman of Research and Development at SmithKline Beecham and he worked for ICI/Zeneca from 1986 to 1997, serving as Executive Vice President and International Research Director from 1994 to 1997.  While at Zeneca and SmithKline Beecham, David oversaw the discovery and development of a number of successful drugs including Seroquel®, Accolate®, Avandia®, and Iressa®.  Following post-doctoral research at the Johns Hopkins University School of Medicine, he was a tenured Associate Professor of Pharmacology and Neurobiology at Northwestern University Medical School.  He has held academic appointments at Johns Hopkins University and the University of Pennsylvania, and is an Honorary Professor at the University of Glasgow.  David received his PhD in Pharmacology from the University of Kansas, and his BS in Pharmacology from the University of Glasgow.  He has authored more than 100 primary and review publications, was a founding co-editor of Molecular Neurobiology, and has served as a member of numerous editorial boards.  David is Chairman of the Board of Cyclacel Pharmaceuticals (Berkeley Heights NJ and Dundee) and a Board Member of Iroko Pharmaceuticals (Philadelphia PA),  past Chairman of PennsylvaniaBio and is Chair of the Advisory Board and member of the Board of Managers of BioMotiv, the for-profit arm of the Harrington Project.

I am delighted to hear that BELS is being reactivated.  As you know, three of my four college degrees were obtained at UK universities and my first professional position was at the MRC Toxicology Unit then based in Carshalton, Greater London. The UK higher education system and the Health and Life Sciences sector were unduly generous to me as I was developing my career. The opportunity to pay back into this sector while strengthening my connections to it is most welcome, and I am certain that many of my expat colleagues feel the same way. 
Dr Stephen Naylor, Chairman & CEO, MaiHealth, Indianapolis, Indiana